<h1 itemprop="aspect"> <strong>Mycophenolate Side Effects</strong></h1><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2012/07/myfortic-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Mycophenolate" title="Mycophenolate" pagespeed_url_hash="2931456372" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><h1>Severe Side Effects of Mycophenolate</h1><ul><li>Increased rates of <a href="http://en.wikipedia.org/wiki/Lymphoma" rel="nofollow" target="_blank">Lymphoma</a> cancer have been reported with Mycophenolate sodium use.</li><li>Increased risk of viral and fungal infections.</li><li>Increased risk of life threatening brain infection (<a href="http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001695/" rel="nofollow" target="_blank">progressive multifocal leukoencephalopathy</a>)</li><li>Mycophenolate may increase the likelihood of developing <strong>skin cancer</strong>.</li><li>Severe gastrointestinal bleeding may occur during use of Mycophenolate sodium.</li></ul><h2>Common Side Effects of Mycophenolate</h2><ul><li>Lowered white blood cell count which increases the risk of various infections.</li><li>High blood pressure</li><li>Increased cholesterol levels</li><li>Anxiety and/or depression</li><li>Anemia</li><li>Constipation</li><li>Urinary tract infection</li></ul></div><div class="v" id="tab2" ><h2 itemprop="aspect"> <strong> Warnings & Recalls for Mycophenolate </strong></h2><h2>Mycophenolate Recalls</h2><ul><li>On June 1st, 2011, Aidapak Services LLC recalled <strong>Mycophenolic Sodium DR</strong> 360 mg <strong></strong> due to <strong>penicillin cross-contamination</strong>.  The NDC (National Drug Code) is 00078-0386-66 and the recall number is D-670-2012.  To view the recalled lots, look under number 177) on the <a href="http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm282335.htm" rel="nofollow" target="_blank"> Enforcement Report for November 30, 2011</a>.</li></ul><ul><li>On November 26th, 2008,<a href="http://www.fda.gov/downloads/Safety/Recalls/EnforcementReports/UCM167873.pdf" rel="nofollow" target="_blank"> Advantage Dose LLC</a> recalled<strong> Myfortic D-R</strong> (Mycophenolic acid) 360mg due to nonconformance of <a href="http://en.wikipedia.org/wiki/Current_good_manufacturing_practice" rel="nofollow" target="_blank"> current good manufacturing practices</a>.   The drug was manufactured by Novartis and the recall number is D-703-2009.  The recalled lot is F0084, and the expiration date is 10/29/09.</li></ul><h2>General Warnings for Mycophenolate</h2><ul><li>Mycophenolate is a pregnancy category class D drug.  According to recent postmarketing data,  Mycophenolate can cause <strong>pregnancy loss</strong> (especially during the first trimester) and<strong> birth defects</strong>.  In animal studies, even small doses caused severe birth defects.</li><li>As with most immunosuppressants, Mycophenolate lowers the body's ability to fight infections and should be prescribed and taken with extreme caution.</li><li>Do not take antacids and mycophenolate simultaneously, as this will decrease absorption of the medication.</li></ul></div><div class="v" id="tab3" ><h2 itemprop="aspect"> <strong> Mycophenolate Treatment and Use </strong></h2><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2012/07/myfortic-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Mycophenolate" title="Mycophenolate" pagespeed_url_hash="2931456372" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><p><strong>Mycophenolate </strong>sodium | Myfortic is an <a target="_blank" href="http://en.wikipedia.org/wiki/Immunosuppressant" rel="nofollow" target="_blank">immunosuppressant</a> that is primarily prescribed to help the body <strong>accept kidney transplants</strong> and generally <strong>prevent transplant rejection</strong>.  It is often combined with cyclosporine and corticosteroids.  Mycophenolate is also used to help treat various autoimmune diseases such as <strong>Lupus</strong> and<strong> Crohn&#8217;s Disease</strong>.  Mycophenolate sodium is marketed as the brand name Myfortic by Novartis, which is a delayed-release formulation.</p><h2>How does Mycophenolate work?</h2><p>Mycophenolate works to target overactive cells so the <strong>immune system</strong> does not attack and <strong>reject a transplanted organ</strong>.  This lowered immune response also helps to stabilize an overactive immune response that often causes or aggravates <strong>autoimmune diseases</strong>.  It was first studied as a potential antibiotic in 1896 but was found to be effective as an immunosuppressant during the 1970&#8242;s.</p><h2>Mycophenolate Dosage</h2><p>Mycophenolate sodium typically comes in 180 and  360 mg enteric coated tablet forms.  The initial dosage for <strong>renal transplant patients</strong> is 720 mg twice a day on an empty stomach.</p><p>For <strong>heart transplant patients</strong>, the dosage may be increased to 2160 mg a day.  It is important to take the tablets either one hour before or two hours after eating, with doses being taken 12 hours apart.</p></div><div class="v" id="tab4" ><h2 itemprop="aspect"> Other Names for Mycophenolate</h2><h2>Brand Names</h2><br/><ul><br/><li>Myfortic</li><br/></ul><br/><h2> Generic Names</h2><br/><ul><br/><li>Mycophenolate Sodium</li><br/><li>Mycophenolic Acid</li><br/></ul></div><div class="v" id="tab5" ><h2 itemprop="aspect"> <strong> Lawsuits & Legal Information for Mycophenolate </strong></h2>